Home › Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis
 

Keywords :   


Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis

2013-07-17 04:00:00| drugdiscoveryonline Home Page

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, recently announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB)

Tags: rights development worldwide exclusive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.06Atlantic Tropical Weather Outlook
02.06Eastern North Pacific Tropical Weather Outlook
02.06Shops rush for Christmas stock as shipping costs surge
02.06Successful entrepreneurs dont worry about being different
02.06Eastern North Pacific Tropical Weather Outlook
02.06Atlantic Tropical Weather Outlook
01.06Mining for Pearlizing Agent 
01.06The Power of Zinc Pyrithione
More »